Showing results (1-10 of 33) with videos related to
Sort By:
Pageof 4
The AAPS Journal|May 30, 2014
Simplification of complex physiologically based pharmacokinetic models of monoclonal antibodiesMohamed Elmeliegy, Philip Lowe, Wojciech KrzyzanskiClinical Pharmacokinetics|February 14, 2020
Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction StudiesMohamed Elmeliegy, Manoli Vourvahis, Cen Guo, et al.Journal of Clinical Pharmacology|April 30, 2026
Limitations of Subgroup Safety Analyses for Drug-Drug Interaction Evaluation: Insights from the Talazoparib P-gp Inhibitor CaseDiane Wang, Charvi Nanavati, Derek Z Yang, et al.Clinical Pharmacology and Therapeutics|December 6, 2021
Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing RecommendationsDerek Z Yang, Ali Alhadab, Kourosh Parivar, et al.Clinical and Translational Science|September 30, 2022
Design and conduct considerations for studies in patients with hepatic impairmentPaulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, et al.Critical Reviews in Oncology/Hematology|January 21, 2023
Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road aheadPooneh Soltantabar, Hoi-Kei Lon, Kourosh Parivar, et al.Cancer Chemotherapy and Pharmacology|August 5, 2020
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemiaMohamed Elmeliegy, Jason Den Haese, Chetasi Talati, et al.Journal of Clinical Pharmacology|December 17, 2025
Elranatamab Exposure-Safety Analysis in Relapsed or Refractory Multiple MyelomaPooneh Soltantabar, Jennifer Hibma, Diane Wang, et al.Journal of Clinical Pharmacology|July 22, 2020
Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology CompoundsMohamed Elmeliegy, Derek Z Yang, Engie Salama, et al.Targeted Oncology|August 20, 2025
Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing ApproachMohamed Elmeliegy, Pooneh Soltantabar, Jennifer Hibma, et al.Pageof 4